Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations

Summary: 

IDH1/2 mutations are commonly found in adult gliomas. Gliomas with these mutations are thought to have a better prognosis than patients without the IDH1/2 mutations, but nearly all patients will eventually recur, and thus better options are needed. A recent discovery was made that IDH1/2 mutations induce a “BRCAness” state. As a result, this makes them sensitive to a class of drugs known as PARP inhibitors. This phase I/II study will assess the safety and overall response rate of pamiparib, a potent PARP inhibitor, in combination with temozolomide, a chemotherapy utilized in neurological cancer, in patients with recurrent IDH1/2 mutated gliomas.

Trial Registration: ClinicalTrials.gov Identifier: NCT03914742